Carmat S.A. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 42.4M
Total Liabilities 93.6M
Shareholders Equity -51.1M

Cash Flow Metrics

Revenue & Profitability Trend

Carmat S.A Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i7.0M2.8M372.0K2.3M0
Cost of Goods Sold i30.6M33.8M28.8M42.8M24.4M
Gross Profit i-23.6M-31.0M-28.4M-40.5M-24.4M
Gross Margin % i-336.6%-1,087.5%-7,647.0%-1,732.7%0.0%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i-----
Other Operating Expenses i6.6M2.4M4.8M2.9M794.0K
Total Operating Expenses i6.6M2.4M4.8M2.9M794.0K
Operating Income i-40.1M-41.0M-44.1M-48.1M-28.9M
Operating Margin % i-573.0%-1,438.7%-11,864.5%-2,058.5%0.0%
Non-Operating Items
Interest Income i121.0K373.0K---
Interest Expense i3.3M3.4M3.8M3.3M2.5M
Other Non-Operating Income-----
Pre-tax Income i-53.1M-55.6M-55.7M-63.7M-38.7M
Income Tax i-1.7M-1.7M-2.1M-1.9M-1.7M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-51.4M-53.9M-53.7M-61.9M-37.0M
Net Margin % i-734.2%-1,891.4%-14,430.1%-2,646.4%0.0%
Key Metrics
EBITDA i-39.8M-34.7M-45.6M-39.7M-20.6M
EPS (Basic) i€-1.15€-2.09€-2.28€-3.97€-2.85
EPS (Diluted) i€-1.15€-2.09€-2.28€-3.97€-2.85
Basic Shares Outstanding i4469130425815625235953401558513912969474
Diluted Shares Outstanding i4469130425815625235953401558513912969474

Income Statement Trend

Carmat S.A Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i4.7M8.0M51.4M39.2M36.0M
Short-term Investments i-----
Accounts Receivable i1.5M1.3M140.0K464.0K-
Inventory i19.8M23.9M17.4M14.3M9.9M
Other Current Assets1.0K-1.0K-1.0K1.0K1.0K
Total Current Assets i32.4M42.4M77.8M61.7M52.9M
Non-Current Assets
Property, Plant & Equipment i21.3M6.2M5.2M5.4M3.8M
Goodwill i73.0K72.0K088.0K17.0K
Intangible Assets i73.0K72.0K-88.0K17.0K
Long-term Investments-----
Other Non-Current Assets12.0K38.0K37.0K8.0K-
Total Non-Current Assets i10.1M10.7M7.5M7.4M7.0M
Total Assets i42.4M53.1M85.2M69.1M59.8M
Liabilities
Current Liabilities
Accounts Payable i5.2M9.6M6.5M8.4M8.0M
Short-term Debt i2.3M-2.6M133.0K79.4K
Current Portion of Long-term Debt-----
Other Current Liabilities4.3M4.9M--14.5M
Total Current Liabilities i19.1M20.4M12.2M13.6M12.4M
Non-Current Liabilities
Long-term Debt i55.5M57.6M55.4M52.0M38.9M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities16.8M16.8M14.5M14.5M14.5M
Total Non-Current Liabilities i74.5M76.4M71.0M69.1M54.1M
Total Liabilities i93.6M96.8M83.3M82.6M66.5M
Equity
Common Stock i1.8M992.0K907.0K623.0K520.0K
Retained Earnings i-98.5M-55.1M-68.9M-98.8M-37.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-51.1M-43.8M2.0M-13.5M-6.7M
Key Metrics
Total Debt i57.8M57.6M58.0M52.2M39.0M
Working Capital i13.3M22.0M65.5M48.1M40.4M

Balance Sheet Composition

Carmat S.A Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-49.2M-52.5M-51.9M-60.4M-37.0M
Depreciation & Amortization i-----
Stock-Based Compensation i-----
Working Capital Changes i000-9.4M-18.6M
Operating Cash Flow i-43.5M-59.4M-52.9M-78.0M-53.0M
Investing Activities
Capital Expenditures i-1.5M-5.0M-1.7M-1.8M-2.3M
Acquisitions i-----
Investment Purchases i-----72.0K
Investment Sales i---13.0K-
Investing Cash Flow i-1.4M-4.9M-2.0M-1.8M-2.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i---10.0M20.0M
Debt Repayment i-831.0K-1.1M-481.0K-255.0K-
Financing Cash Flow i41.4M15.0M68.6M65.1M25.8M
Free Cash Flow i-44.8M-58.5M-56.1M-61.9M-45.4M
Net Change in Cash i-3.5M-49.3M13.7M-14.6M-29.6M

Cash Flow Trend

Carmat S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -0.11
Forward P/E -0.05
Price to Sales 1.09
PEG Ratio -0.05

Profitability Ratios

Profit Margin -336.56%
Operating Margin -644.75%
Return on Equity 100.52%
Return on Assets -64.45%

Financial Health

Current Ratio 1.68
Debt to Equity -1.13
Beta 1.37

Per Share Data

EPS (TTM) €-1.15
Book Value per Share €-0.81
Revenue per Share €0.16

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
alcar8.6M-0.11-100.52%-336.56%-1.13
Guerbet S.A 341.6M15.280.623.50%1.89%100.91
Eurobio Scientific 253.4M64.871.422.26%2.58%5.46
Median Technologies 87.8M-1.75-74.31%-109.93%-0.98
Affluent Medical 59.2M-3.851.83-48.69%-275.50%0.54
Novacyt S.A 34.8M-0.800.70-57.28%-212.73%24.81

Financial data is updated regularly. All figures are in the company's reporting currency.